ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1148

Adalimumab – Effective Control under Refractory JIA Associated Uveitis

Ekaterina Alekseeva1, Elena Mitenko2, Tatyana Bzarova2, Saniya Valieva2, Kseniya Isayeva2, Alexandra Chomakhidze2, Evgeniya Chistyakova2, Tatyana Sleptsova2 and Rina Denisova2, 1PRINTO, Genoa, Italy, 2Rheumatology, Scientific Center of Children's Health, Moscow, Russia

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab and juvenile arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis  is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX, CiA and topical NSAIDs and GC. Humanised anti-TNFα monoclonal antibody (adalimumab) may be effective drug for the treatment of JIA-associated uveitis refractory to immunosuppressive drugs. Objectives: To evaluate clinical efficacy and safety of adalimumab therapy in patients with JIA-associated uveitis.

Methods: It was prospective, observational trial. 48 patients with uveitis were enrolled in the study, 8 boys and 40 girls, 32–with bilateral and 16-with unilateral uveitis, 27 had poly-, 21-oligoarthritis. Mean age of patients was 11,8 (range 4–18) y; mean of disease duration–5,7 (range 1–16) y. Before adalimumab therapy 10 patients were treated with MTX (range of dose 15-25 mg/m2/w), 38–with MTX in combination with CiA (range of dose 4-4,5 mg/kg/d), 5 – with oral GC (range of dose 5-12 mg/kg/d), all of them–with topical GC drops, NSAID drops, 27 –received retrobulbar injections of GC. Adalimumab was administrated by subcutaneous injection at dose 40 mg every 2 w during 1y. Adalimumab use was approved by the Local Ethics Committee. The efficacy of therapy was measured by ACR-pedi criteria. Changes in ocular inflammation were graded by M.J.Hogan’s criteria. The main target – remission of uveitis and arthritis.

Results: Prior to administration of adalimumab, injection of conjunctiva, edema of iris, corneal precipitations, areas of inflammation in lens and optical nerve disk edema were found in all children with uveitis. After 8 w of treatment complete management of conjunctiva injection, iris edema and optical nerve disk edema were reported in 55%(44/80) of the affected eyes –  corneal precipitations disappeared in 45%(36/80); inflammation-associated changes of lens – in 18%(14/80) of eyes. Treatment-associated improvement of vision was found in 63 of 80 of the affected eyes; no changes of vision acuity were reported in 33(41%) of the affected eyes. GC eye drops were discontinued in 45%(22/48) of patients, NSAIDs eye drops – in 50%(24/48) of children; the dose of GC eye drops was reduced in 86%(41/48) of patients. The exacerbation of uveitis was persisting in 10%(8/80) of the affected eyes, subacute uveitis – in 25%(20/80); remission was found in 65%(52/80) of the affected eyes. After 24 w of treatment the cases of uveitis were not reported; subacute disease was observed in 22%(21/96) of eyes; remission was diagnosed in 78%(62/80) of the affected eyes. After 52 w of treatment remission was diagnosed in 83% of the affected eyes (66/80) The ACR-Pedi 30, 50, 70 were achieved 100%, 80%, 60% of patients at w 4, respectively. After 24 w of therapy ACR-Pedi 30,50,70 and 90 improvements rates was registrated in 100 %,92 %,78 % of patients. The remission was achieved by 63% of patient at w 52. Serious adverse events were not found.

Conclusion: Adalimumab is effective in patients with JIA associated uveitis. Reduction in uveitis activity and remission were reported in 83% of affected eyes. Remission of disease – in 63% of patients.The high efficacy of adalimumab allowed avoiding oral prednisolone and discontinuing topical GC therapy in patients with uveitis.


Disclosure:

E. Alekseeva,
None;

E. Mitenko,
None;

T. Bzarova,
None;

S. Valieva,
None;

K. Isayeva,
None;

A. Chomakhidze,
None;

E. Chistyakova,
None;

T. Sleptsova,
None;

R. Denisova,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adalimumab-effective-control-under-refractory-jia-associated-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology